Related references
Note: Only part of the references are listed.Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum beta-lactamase
David Skurnik et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2010)
In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study
Stephen P. Hawser et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective
Ann L. N. Chapman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Efficacy of ertapenem for consolidation therapy of extended-spectrum β-lactamase-producing gram-negative infections:: A case series report
Melody L. Berg et al.
ANNALS OF PHARMACOTHERAPY (2008)
Extended-spectrum beta-lactamase-producing enterobacteriaceae: an emerging public-health concern
Johann D. D. Pitout et al.
LANCET INFECTIOUS DISEASES (2008)
Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community
JDD Pitout et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide:: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)
DL Paterson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Antibiotic therapy for Klebsiella pneumoniae bacteremia:: Implications of production of extended-spectrum β-lactamases
DL Paterson et al.
CLINICAL INFECTIOUS DISEASES (2004)
Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme - A Canadian teaching hospital and ministry of health perspective
AO Wai et al.
PHARMACOECONOMICS (2000)
Share Paper
